As personalisation based on mutational profile is increasingly common in routine clinical practice, for example through FDA- and EMA-licensed therapies for patients whose tumours bear FGFR2 fusions or IDH1 mutations,1 we sought to define recommendations that serve to maximise the overall clinical value of tissue sampling for the management of patients with iCCA. This evidence concerns the gene FGFR2 and neoplasm.